Print
Email
Print Edition Stories
MHT's Marc Songini: Researchers focus on macular degeneration
MHT's Marc Songini: RI plans launch of cord blood center
The University of Rhode Island reports researcher Annie DeGroot has landed a $13 million grant from the National Institutes of Health to develop a multidisciplinary program to develop vaccines for infectious diseases.
The research is being led by DeGroot, the director of the school’s Institute for Immunology and Informatics, and the CEO of Providence-based biotech EpiVax Inc.
The project, called the Translational Immunology Research and Accelerated Vaccine Development (TRIAD) program, is intended to design vaccines with a mix of computer simulation, and in vitro and in vivo research. The research will focus on infectious diseases such as Heptatitis C, disease-causing bacteria like Helicobacter pylori and engineered biowarfare/bioterror agents.
URI researcher Thomas Mather will also direct a project on the development of a vaccine against a range of tick-borne diseases. URI will collaborate with EpiVax and Providence-based hospital system Lifespan on the project.
The funding will allow DeGroot to hire eight staff members at the Institute. The funding will also support a training course and pilot grants for researchers interested in using new vaccine design tools developed by the program.
In May, URI’s college of pharmacy landed an $18 million NIH grant for research on molecular toxicology, cell biology and behavioral science.
DeGroot joined the URI faculty in February.
Add your comment, and share it via Facebook, LinkedIn, Yahoo and more. Edit your Disqus profile settings.
RSS Feeds
